Description: Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
Home Page: www.cabalettabio.com
CABA Technical Analysis
2929 Arch Street
Philadelphia,
PA
19104
United States
Phone:
267 759 3100
Officers
| Name | Title |
|---|---|
| Dr. Steven A. Nichtberger M.D. | Co-Founder, Chairman, CEO & Pres |
| Dr. Gwendolyn K. Binder Ph.D. | Pres of Science & Technology |
| Dr. David J. Chang FACR, M.D., M.P.H. | Chief Medical Officer |
| Dr. Michael C. Milone M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board |
| Dr. Aimee Payne M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board |
| Mr. Anup Marda M.B.A. | Chief Financial Officer |
| Dr. Samik Basu M.D. | Chief Scientific Officer |
| Mr. Michael Gerard J.D. | Gen. Counsel & Sec. |
| Ms. Heather Harte-Hall M.Sc. | Chief Compliance Officer |
| Ms. Martha O'Connor | Chief HR Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3109 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-10-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 57 |